Exicure, Inc. (XCUR) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Exicure, Inc. is a former early-stage biotechnology company that suspended all research and development activities in September 2022. The company is currently focused on exploring strategic alternatives, including licensing its intellectual property and seeking a strategic transaction to maximize stockholder value. The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $500,000 | $0 |
| Net Loss | $(600,000) | $(1,429,000) | $(10,171,000) |
| Operating Expenses | $1,235,000 | $2,571,000 | $10,181,000 |
| Cash & Equivalents (End of Period) | $528,000 | $528,000 | $816,000 (Dec 31, 2023) |
| Total Debt (Short-term) | $1,000,000 | $1,000,000 | $0 |
| Stockholders' Equity | $1,613,000 | $1,613,000 | $3,031,000 (Dec 31, 2023) |
Note: Revenue for the six months ended June 30, 2024, consists of a $500,000 upfront payment from a patent license agreement and $637,000 in "Other income" from the sale of clinical product samples.
Material Changes vs. Prior Period
- Expense Reduction: Operating expenses decreased significantly by 78% in Q2 2024 compared to Q2 2023 ($1.2M vs. $5.6M) and 75% on a year-to-date basis. This reduction is attributed to the suspension of R&D activities, reduced headcount (5 full-time employees vs. 7 in 2023), and lower professional fees.
- Revenue Generation: The company generated $500,000 in revenue in Q1 2024 from a new patent license agreement for cavrotolimod, a historical asset, and recognized $637,000 in other income in Q2 from sample sales. This contrasts with zero revenue in the prior year periods.
- Debt Incurrence: The company incurred $1,000,000 in short-term debt during the first half of 2024 (a $300,000 note from an individual investor and a $700,000 note from a related party, DGP).
- Asset Write-down: A $2.0 million investment in convertible notes receivable was written down to $0 fair value as management does not believe they are recoverable following failed redemption attempts.
Outlook, Risks, and Management Commentary
- Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern. With only $528,000 in cash and cash equivalents, the company requires substantial additional financing in the very near term to fund operations and strategic exploration. Failure to raise capital could lead to bankruptcy or cessation of operations.
- Nasdaq Compliance: The company is not in compliance with Nasdaq listing requirements regarding minimum bid price (stock trading below $1.00) and minimum stockholders' equity ($1.6M vs. required $2.5M). The company received a delisting determination but was granted an extension by the Nasdaq Hearings Panel to cure deficiencies by September 16, 2024. A special stockholder meeting is scheduled for August 15, 2024, to vote on a reverse stock split.
- Legal Proceedings: A putative securities class action lawsuit (Colwell v. Exicure) reached an agreement in principle to settle in August 2024, subject to court approval. Several shareholder derivative lawsuits remain stayed pending the outcome of the class action.
- Internal Controls: The company identified material weaknesses in internal controls over financial reporting, specifically regarding the classification of expenses and review of non-routine activities. Disclosure controls and procedures were deemed ineffective.
Investor Verification Checklist
- Liquidity Runway: Verify the timeline for securing new financing given the $528k cash balance and substantial doubt disclosure.
- Nasdaq Delisting Risk: Monitor the outcome of the August 15, 2024, stockholder meeting regarding the reverse stock split and the company's ability to meet the September 16, 2024, compliance deadline.
- Debt Obligations: Review the terms of the $1M short-term debt (6% interest) and the potential impact of the related-party loan from DGP.
- Asset Recovery: Assess the likelihood of recovering the $2M convertible notes receivable, which are currently valued at $0.
- Strategic Alternatives: Evaluate the progress of the exploration for strategic transactions or asset sales, as the company has no significant ongoing revenue source.